Tae-Hyeon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tae-Hyeon Kim has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Do Kyung Kim
Professor, Institute of Dental Science, Chosun University, Gwangju, Republic of Korea
2 shared publications - Hong Sung Chun
Department of Biomedical Science, Chosun University
2 shared publications - HyangI Lim
Master’s Degree, Institute of Dental Science, Chosun University, Jeonnam-Gwangju, Republic of Korea
2 shared publications - Jae-Sung Kim
Professor, Institute of Dental Science, Chosun University, Gwangju, Republic of Korea
2 shared publications - Jeong-Yeon Seo
Ph.D. Student, Department of Oral Physiology, School of Dentistry, Chosun University, Gwangju, Republic of Korea
2 shared publications - Kyeong-Rok Kang
Postdoc Research Assistant, Institute of Dental Science, Chosun University, Jeonnam-Gwangju, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6993
Doxorubicin-Incorporated Nanoparticles Composed of Ce6-Conjugated Hyaluronic Acid-b-poly(ethylene glycol) Copolymer for Overcoming Doxorubicin Resistance of Breast Cancer Cells
Oxidative stress in the tumor microenvironment, which is its own intrinsic property, is frequently utilized to deal with the drug-targeting issue in the nanoparticle drug delivery system. For this purpose, reactive oxygen species (ROS)-sensitive nanoparticles encapsulating doxorubicin (DOX) and chlorin e6 (Ce6) were synthesized for treatment of MDA-MB-231 breast cancer cells. Hyaluronic acid (HA) with a reductive end was conjugated with methoxy poly(ethylene glycol) (PEG) using thioketal diamine (ThdNH2) linkage (HA-b-PEG copolymer). Then, Ce6 were conjugated to the carboxylic acid group of HA via ThdNH2 (HA(Ce6)-b-PEG copolymer). DOX was physically incorporated to make DOX-incorporated HA(Ce6)-b-PEG copolymer nanoparticles (DOX-NP). HA(Ce6)-b-PEG copolymer nanoparticles (empty NP) and DOX-NP have a tiny particle size, less than 200 nm, with spherical morphology. They were responsively disintegrated according to the hydrogen peroxide (H2O2) concentration, then the release rate of Ce6 or DOX was accelerated, indicating that empty NP and DOX-NP have ROS sensitivity. DOX-resistant MDA-MB-231 cells were prepared by continuous treatment of DOX for three months. DOX-NP were efficiently internalized into the cells while intra-cellular delivery of DOX itself was inhibited. DOX-NP has higher anticancer activity against DOX-resistant MDA-MB-231 cells than that of DOX itself since cells were resistant to DOX itself. Under light irradiation, DOX-NP significantly decreased the viability of DOX-resistant MDA-MB-231 cells while DOX itself did not properly affect cell viability. Empty NP also efficiently inhibited cell viability rather than that of Ce6 itself while both of them did not affect the cell viability in the absence of light irradiation. Furthermore, empty NP showed higher ROS generation than that of Ce6 itself. DOX-NP more efficiently induced apoptosis/necrosis than DOX itself. In DOX-resistant MDA-MB-231 cell-bearing mice, DOX-NP was efficiently delivered to tumor tissue. DOX-NP greatly inhibited the growth of tumors under light irradiation, more than that of DOX itself or empty NP. In conclusion, DOX-NP showed promising antitumor activity against DOX-resistant MDA-MB-231 cells.
- 4 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6993
Open AccessDoxorubicin-Incorporated Nanoparticles Composed of Ce6-Conjugated Hyaluronic Acid-b-poly(ethylene glycol) Copolymer for Overcoming Doxorubicin Resistance of Breast Cancer Cells
Oxidative stress in the tumor microenvironment, which is its own intrinsic property, is frequently utilized to deal with the drug-targeting issue in the nanoparticle drug delivery system. For this purpose, reactive oxygen species (ROS)-sensitive nanoparticles encapsulating doxorubicin (DOX) and chlorin e6 (Ce6) were synthesized for treatment of MDA-MB-231 breast cancer cells. Hyaluronic acid (HA) with a reductive end was conjugated with methoxy poly(ethylene glycol) (PEG) using thioketal diamine (ThdNH2) linkage (HA-b-PEG copolymer). Then, Ce6 were conjugated to the carboxylic acid group of HA via ThdNH2 (HA(Ce6)-b-PEG copolymer). DOX was physically incorporated to make DOX-incorporated HA(Ce6)-b-PEG copolymer nanoparticles (DOX-NP). HA(Ce6)-b-PEG copolymer nanoparticles (empty NP) and DOX-NP have a tiny particle size, less than 200 nm, with spherical morphology. They were responsively disintegrated according to the hydrogen peroxide (H2O2) concentration, then the release rate of Ce6 or DOX was accelerated, indicating that empty NP and DOX-NP have ROS sensitivity. DOX-resistant MDA-MB-231 cells were prepared by continuous treatment of DOX for three months. DOX-NP were efficiently internalized into the cells while intra-cellular delivery of DOX itself was inhibited. DOX-NP has higher anticancer activity against DOX-resistant MDA-MB-231 cells than that of DOX itself since cells were resistant to DOX itself. Under light irradiation, DOX-NP significantly decreased the viability of DOX-resistant MDA-MB-231 cells while DOX itself did not properly affect cell viability. Empty NP also efficiently inhibited cell viability rather than that of Ce6 itself while both of them did not affect the cell viability in the absence of light irradiation. Furthermore, empty NP showed higher ROS generation than that of Ce6 itself. DOX-NP more efficiently induced apoptosis/necrosis than DOX itself. In DOX-resistant MDA-MB-231 cell-bearing mice, DOX-NP was efficiently delivered to tumor tissue. DOX-NP greatly inhibited the growth of tumors under light irradiation, more than that of DOX itself or empty NP. In conclusion, DOX-NP showed promising antitumor activity against DOX-resistant MDA-MB-231 cells.
- Open Access
- 10 March 2023
- Published by Elsevier in Molecules and Cells
- Vol. 46 (4) , 245-255
7α,25-Dihydroxycholesterol-Induced Oxiapoptophagic Chondrocyte Death via the Modulation of p53-Akt-mTOR Axis in Osteoarthritis Pathogenesis
Jeong-Yeon Seo, Tae-Hyeon Kim, Kyeong-Rok Kang, HyangI Lim, Moon-Chang Choi, Do Kyung Kim, Hong Sung Chun, Heung-Joong Kim, Sun-Kyoung Yu, and Jae-Sung Kim. Mol. Cells 2023;46:245-55. https://doi.org/10.14348/molcells.2023.2149
- 10 March 2023
- Published by Elsevier in Molecules and Cells
- Vol. 46 (4) , 245-255
Open Access7α,25-Dihydroxycholesterol-Induced Oxiapoptophagic Chondrocyte Death via the Modulation of p53-Akt-mTOR Axis in Osteoarthritis Pathogenesis
Jeong-Yeon Seo, Tae-Hyeon Kim, Kyeong-Rok Kang, HyangI Lim, Moon-Chang Choi, Do Kyung Kim, Hong Sung Chun, Heung-Joong Kim, Sun-Kyoung Yu, and Jae-Sung Kim. Mol. Cells 2023;46:245-55. https://doi.org/10.14348/molcells.2023.2149
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Acteoside Counteracts Interleukin‐1β‐Induced Catabolic Processes through the Modulation of Mitogen‐Activated Protein Kinases and the NFκB Cellular Signaling Pathway
Osteoarthritis (OA) is the most common degenerative joint disease with chronic joint pain caused by progressive degeneration of articular cartilage at synovial joints. Acteoside, a caffeoylphenylethanoid glycoside, has various biological activities such as antimicrobial, anti‐inflammatory, anticancer, antioxidative, cytoprotective, and neuroprotective effect. Further, oral administration of acteoside at high dosage does not cause genotoxicity. Therefore, the aim of present study is to verify the anticatabolic effects of acteoside against osteoarthritis and its anticatabolic signaling pathway. Acteoside did not decrease the viabilities of mouse fibroblast L929 cells used as normal cells and primary rat chondrocytes. Acteoside counteracted the IL‐1β‐induced proteoglycan loss in the chondrocytes and articular cartilage through suppressing the expression and activation of cartilage‐degrading enzyme such as matrix metalloproteinase‐ (MMP‐) 13, MMP‐1, and MMP‐3. Furthermore, acteoside suppressed the expression of inflammatory mediators such as inducible nitric oxide synthase, cyclooxygenase‐2, nitric oxide, and prostaglandin E2 in the primary rat chondrocytes treated with IL‐1β. Subsequently, the expression of proinflammatory cytokines was decreased by acteoside in the primary rat chondrocytes treated with IL‐1β. Moreover, acteoside suppressed not only the phosphorylation of mitogen‐activated protein kinases in primary rat chondrocytes treated with IL‐1β but also the translocation of NFκB from the cytosol to the nucleus through suppression of its phosphorylation. Oral administration of 5 and 10 mg/kg acteoside attenuated the progressive degeneration of articular cartilage in the osteoarthritic mouse model generated by destabilization of the medial meniscus. Our findings indicate that acteoside is a promising potential anticatabolic agent or supplement to attenuate or prevent progressive degeneration of articular cartilage.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessActeoside Counteracts Interleukin‐1β‐Induced Catabolic Processes through the Modulation of Mitogen‐Activated Protein Kinases and the NFκB Cellular Signaling Pathway
Osteoarthritis (OA) is the most common degenerative joint disease with chronic joint pain caused by progressive degeneration of articular cartilage at synovial joints. Acteoside, a caffeoylphenylethanoid glycoside, has various biological activities such as antimicrobial, anti‐inflammatory, anticancer, antioxidative, cytoprotective, and neuroprotective effect. Further, oral administration of acteoside at high dosage does not cause genotoxicity. Therefore, the aim of present study is to verify the anticatabolic effects of acteoside against osteoarthritis and its anticatabolic signaling pathway. Acteoside did not decrease the viabilities of mouse fibroblast L929 cells used as normal cells and primary rat chondrocytes. Acteoside counteracted the IL‐1β‐induced proteoglycan loss in the chondrocytes and articular cartilage through suppressing the expression and activation of cartilage‐degrading enzyme such as matrix metalloproteinase‐ (MMP‐) 13, MMP‐1, and MMP‐3. Furthermore, acteoside suppressed the expression of inflammatory mediators such as inducible nitric oxide synthase, cyclooxygenase‐2, nitric oxide, and prostaglandin E2 in the primary rat chondrocytes treated with IL‐1β. Subsequently, the expression of proinflammatory cytokines was decreased by acteoside in the primary rat chondrocytes treated with IL‐1β. Moreover, acteoside suppressed not only the phosphorylation of mitogen‐activated protein kinases in primary rat chondrocytes treated with IL‐1β but also the translocation of NFκB from the cytosol to the nucleus through suppression of its phosphorylation. Oral administration of 5 and 10 mg/kg acteoside attenuated the progressive degeneration of articular cartilage in the osteoarthritic mouse model generated by destabilization of the medial meniscus. Our findings indicate that acteoside is a promising potential anticatabolic agent or supplement to attenuate or prevent progressive degeneration of articular cartilage.